Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Marshall Edwards has received new US patent, 8,080,675, covering isoflavone-based compounds, including lead oncology drug candidates ME-143 and ME-344, and their pharmaceutical compositions.
Subscribe to our email newsletter
The new patent is estimated to provide protection until March 2027.
Marshall CEO and president Daniel Gold said the patent represents another important milestone in their efforts to develop lead drug candidates into valuable treatment options for patients with cancer.
"Furthermore, this demonstrates our commitment to further strengthening the intellectual property portfolio we acquired earlier this year, which will be essential for partnering any of our drug candidates," Gold added.